Trial Profile
VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Denosumab; Dexamethasone; Gallium (68Ga) gozetotide; Zoledronic acid
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms VISION
- Sponsors Endocyte
- 01 Apr 2024 Results evaluating the safety of additional cycles of 177Lu-PSMA-617 and the impact of longer observation time for patients receiving 177Lu-PSMA-617 plus SoC published in the European Urology
- 10 Jan 2024 Status changed from active, no longer recruiting to completed.
- 05 Jan 2024 This trial has been completed in France (Global end date: 14 Dec 2023).